Unless they've finally learned to avoid pr because it's counterproductive and instead will let the facts speak for themselves.
I honestly think it's his sports background, full of hyperbole and coach-seak
In real life I'm a lawyer, everything to me is arguable both ways and shades of gray . . .
Not sure how objective this coverage is, see final sentence, seems to be in their client's interest to increase the PPS:
"The Series G Preferred is convertible at a fixed price of $0.06 per share, with no ratchet anti-dilution provisions, and has a six-year maturity term at which time it will automatically convert into Common Stock at $0.06 per share. It bears an annual dividend rate of 8.25%, subject to credit risk adjustment based on the price of the Company's common stock measured over a specific time period. The dividend is payable annually in cash or common stock at the sole discretion of the Company. No warrants were issued to any parties in connection with this investment. Discover has agreed to 'no shorting' provisions. The Series G Preferred can be repurchased by the Company for cash at 120% of face value in conjunction with an up-listing to a national stock exchange. WallachBeth Capital Markets served as financial advisor on the transaction"
Hopefully - not sure just how much positive impact it will have on PPS, but the ability of a new class of investors to acquire shares surely must help? Anyone aware of any studies or anecdotal examples on effect on a biotech PPS of uplisting from OTC?
I'd say it differently. Gerald's unjustified and unfulfilled promises artificially inflated the share price in the past, and caused me to pay too much for my shares. I'm holding in the hope pipeline could still hit.
Dribs and drabs. When and if uplist occurs, post-uplist trading will be far more relevant and indicative of market price
Has there been any specific info on planned uplist date at least approximately, assuming all goes according to plan? I understand that certain time periods must pass and certain criteria must be met, but has company ever said "date X expected"
You remind me of Spock's quote from the episode "I, Mudd": "Logic is a wreath of pretty flowers that smell bad. Are you sure your circuits are registering correctly?"
I sure hope so and also believe that should be the case. My further hope is that AMBS management has learned its lesson and there are no more BS proclamations, but time will tell and market certainly doesn't trust current mgmt. Supposed upcoming R/S - uplist will be a good indicator of how to calibrate the BS meter going forward